Same is true when discussing Donepezil, which apart from being intended as a acetylcholinesterase inhibitor also happens to be an S1R agonists, although I have only read recent papers where that fact has been investigated.
S1R modulation didn’t seem to be an intended effect by those who brought the drug to market.
Now it seems likely that what little positive effect DZP has could be more or less due to its S1R agonism.
Market Data 
Markets 
AI
